查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1990072

霍亂疫苗市場：2026-2032年全球市場預測（依疫苗類型、給藥途徑、劑型、包裝、年齡層、應用、最終用戶和分銷管道分類）

Cholera Vaccines Market by Vaccine Type, Route Of Administration, Dosage Form, Presentation Type, Age Group, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，霍亂疫苗市值將達到 3.2981 億美元，到 2026 年將成長至 3.5318 億美元，到 2032 年將達到 5.4959 億美元，複合年成長率為 7.56%。

主要市場統計數據
基準年 2025 3.2981億美元
預計年份：2026年 3.5318億美元
預測年份 2032 5.4959億美元
複合年成長率 (%) 7.56%

為公共衛生領導者和產業相關人員提供權威的介紹，概述了霍亂疫苗的最新發展、供應挑戰和策略重點。

霍亂仍然是全球公共衛生關注的焦點，而不斷發展的疫苗模式對於預防和控制疫情至關重要。本執行摘要整合了產品創新、監管環境、通路和相關人員採納方面的關鍵進展，旨在為公共衛生領導者、生產商和投資者提供資訊。它簡潔地概述了霍亂疫苗技術的現狀、影響疫苗取得和供應的因素，以及指導採購和部署的實際考慮。

疫苗配方創新、適應性監管途徑以及對加速疫苗部署和普及的計劃的期望不斷變化，正在推動疫苗領域發生顯著變化。

霍亂疫苗領域正經歷一場變革，其驅動力包括科學創新、新的政策重點以及供應鏈結構的改進。製劑技術的進步使得口服製劑更加穩定，部分產品的耐熱性也提升。這減輕了低溫運輸的負擔，並拓寬了可行的經銷模式。同時，一些地區的監管路徑也變得更加靈活，加快了在疫情中展現出顯著療效的疫苗的審查。

分析美國將於 2025 年推出的新關稅對供應鏈、供應商選擇和採購慣例。

美國2025年實施的關稅政策為全球霍亂疫苗生態系統中的製造商、經銷商和採購負責人帶來了新的營運考量。進口關稅及相關合規要求的變化正在影響某些零件和成品的成本結構，促使供應鏈相關人員重新審視籌資策略以及與國際合作夥伴的合約條款。為此，一些製造商正加強提高零件的本地化生產，並對替代供應商進行認證，以維持供應的連續性並降低關稅變化帶來的風險。

基於詳細細分的洞察揭示了疫苗類型、給藥途徑、配方、劑型、分銷、最終用戶、年齡層和應用如何決定產品類型和方案選擇。

細分市場洞察揭示了產品特性和給藥方式如何影響臨床效用、商業策略和專案適用性。根據疫苗類型，該領域區分注射劑和口服疫苗，每種疫苗都有其獨特的臨床、物流和接受度的考量。注射劑疫苗適用於尋求持久免疫反應的臨床環境，而口服疫苗通常優先考慮大規模免疫接種宣傳活動和快速疫情應對中的便捷給藥方式。根據給藥途徑，肌肉注射和口服給藥之間的差異會影響醫護人員培訓、病患接受度和醫療服務場所的選擇。肌肉注射通常需要經過訓練的人員和醫療廢棄物銳器管理，而口服給藥則可減輕這些操作負擔，並擴大社區宣傳活動的覆蓋範圍。

影響美洲、歐洲、中東和非洲以及亞太地區監管方式、採購模式、製造合作和部署策略的區域趨勢。

區域趨勢對霍亂疫苗接種計畫的政策重點、監管方式和供應鏈發展有顯著影響。在美洲，公共衛生系統傾向於優先將疫苗納入既定的免疫接種計劃，並制定應對局部疫情的緊急時應對計畫，同時輔以強調透明合約和集中分發的公共採購框架。相較之下，在歐洲、中東和非洲（EMEA）地區，由於法規環境和衛生系統能力存在差異，區域協調機制和捐助者資助的舉措在確保疫苗取得平等和規範緊急應變通訊協定發揮重要作用。

企業策略方向和夥伴關係模式，透過製造規模、平台創新和對專案支援的承諾來定義競爭優勢。

主要企業之間的競爭格局反映了它們在創新、供應合約以及與公共衛生組織夥伴關係方面的不同策略。一些組織優先投資於能夠快速迭代開發口服和注射疫苗候選產品的平台，而其他組織則專注於最佳化生產流程，並擴大填充和包裝能力，以滿足大規模宣傳活動的需求。商業製造商與全球衛生組織之間的策略聯盟日益普遍，其重點在於共同努力，確保疫苗價格合理、供應穩定，並能惠及服務不足的人。

為製造商和公共衛生合作夥伴制定可操作的、優先考慮的策略行動，以協調產品設計、供應彈性、定價和專案支持，從而產生最大影響。

針對產業領導者的實際建議強調，應將科學研發與實際供應鏈和相關人員合作結合。首先，應優先考慮產品設計決策，充分考慮最終用戶需求和分銷實際情況，透過配方和包裝選擇來減少物流摩擦，從而支持對感染疾病疫情的快速反應。其次，應投資於多元化的供應商網路和區域製造合作夥伴關係，以減輕貿易和關稅的影響，同時增強應對力。第三，應將培訓、低溫運輸創新和部署後監測等項目支援整合到商業性夥伴關係中，並加強與衛生部門和採購負責人的關係。

結合專家訪談、文獻整合和三角測量分析的穩健混合方法研究框架，確保了基於證據的、可操作的見解。

本報告的調查方法採用混合式研究方法，結合了全面的文獻整合、專家訪談以及對政策和採購文件的定性分析。主要研究包括與疫苗研發人員、供應鏈專家和免疫專案管理人員進行結構化諮詢，以收集有關營運挑戰和機會的第一手觀點。次要研究則整合了同行評審的研究、監管文件和專案指南，以支持報告主題並確保說明基於證據。

這些具有前瞻性的結論強調了創新、供應韌性和相關人員合作的必要整合，才能將疫苗研發進展轉化為公共衛生成果。

總之，霍亂疫苗領域正處於一個轉折點，科學進步、供應鏈現代化和不斷變化的政策需求相互交織，重塑疫苗的研發、採購和分發方式。配方和給藥方法的創新拓展了公共衛生工作者可用的工具，而貿易和採購慣例的改變則凸顯了各相關人員相關者運作靈活性的必要性。因此，能夠整合卓越技術、切實有效的專案支援和穩健的商業策略的組織才能最終取得成功。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：霍亂疫苗市場：依疫苗類型分類

  • 注射疫苗
  • 口服疫苗

第9章：霍亂疫苗市場：依給藥途徑分類

  • 肌肉內部
  • 口服

第10章：霍亂疫苗市場：以劑型分類

  • 液體
  • 冷凍乾燥

第11章 霍亂疫苗市場：依包裝類型分類

  • 多次給藥
  • 單一劑量

第12章：霍亂疫苗市場：依年齡層別分類

  • 成人版
  • 老年人
  • 兒童

第13章：霍亂疫苗市場：依應用領域分類

  • 為了預防
  • 治療

第14章 霍亂疫苗市場：依最終用戶分類

  • 門診部
  • 診所
  • 醫院
  • 研究設施

第15章：霍亂疫苗市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第16章 霍亂疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第17章 霍亂疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第18章 霍亂疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章：美國：霍亂疫苗市場

第20章：中國：霍亂疫苗市場

第21章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech International Limited
  • Emergent BioSolutions Inc.
  • EuBiologics Co. Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis AG
  • PaxVax Inc.
  • Pfizer Inc.
  • Sanofi Pasteur SA
  • Serum Institute of India Pvt. Ltd.
  • Shantha Biotechnics Limited
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
Product Code: MRR-5D693B46BD1B

The Cholera Vaccines Market was valued at USD 329.81 million in 2025 and is projected to grow to USD 353.18 million in 2026, with a CAGR of 7.56%, reaching USD 549.59 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 329.81 million
Estimated Year [2026] USD 353.18 million
Forecast Year [2032] USD 549.59 million
CAGR (%) 7.56%

An authoritative introduction that frames current cholera vaccine advancements, delivery challenges, and strategic priorities for public health leaders and industry stakeholders

Cholera remains a global public health concern, and the evolving landscape of vaccines is central to prevention and outbreak control strategies. This executive summary synthesizes critical developments across product innovation, regulatory progress, distribution channels, and stakeholder adoption to inform public health leaders, manufacturers, and investors. It provides a concise but comprehensive orientation to the current state of cholera vaccine technologies, the forces reshaping access and delivery, and the practical considerations that guide procurement and deployment.

In the following pages, readers will find context on vaccine types, administration routes, formulation choices, presentation formats, and end-user settings, as well as the implications of geopolitical and trade dynamics. The summary is designed to be actionable: it highlights where scientific advances intersect with programmatic realities and where commercial opportunities align with public health priorities. By framing these themes up front, decision-makers can rapidly identify candidate areas for deeper investigation and immediate action.

Compelling landscape shifts driven by formulation innovation, adaptive regulatory pathways, and evolving programmatic expectations that accelerate vaccine deployment and access

The cholera vaccine landscape is undergoing transformative shifts driven by scientific innovation, renewed policy attention, and improvements in supply chain architecture. Advances in formulation science have enabled more stable oral preparations and improved thermostability for some products, which in turn ease cold-chain burdens and broaden the range of feasible distribution models. Parallel to these technological changes, regulatory pathways have become more adaptive in several jurisdictions, facilitating accelerated reviews for vaccines that demonstrate demonstrable benefits in outbreak contexts.

At the same time, stakeholder expectations are evolving. Public health authorities increasingly demand evidence of real-world effectiveness and programmatic suitability, not just immunogenicity. Funders and procurement agencies are prioritizing vaccines that can be deployed quickly in emergency settings and that integrate into routine immunization programs. Consequently, manufacturers are balancing investment between novel platforms and incremental improvements to existing oral and injectable offerings. Taken together, these shifts are reshaping competitive dynamics, opening new channels for collaboration, and elevating the importance of integrated planning across clinical, regulatory, and supply functions.

Analysis of the operational and strategic effects of newly implemented United States tariffs in 2025 on supply chains, sourcing choices, and procurement practices

Tariff policies enacted by the United States in 2025 have introduced additional operational considerations for manufacturers, distributors, and procurers engaged in the global cholera vaccine ecosystem. Changes in import duties and related compliance requirements have affected the cost profile of certain components and finished products, prompting supply chain stakeholders to reassess sourcing strategies and contractual terms with international partners. In response, some manufacturers have intensified efforts to localize component production or to qualify alternative suppliers to maintain continuity of supply and to mitigate exposure to tariff volatility.

Furthermore, procurement teams and international agencies have adapted tender structures and pricing negotiations to reflect the new trade environment. These adaptations include longer-term supply agreements with clearer allocation terms and contingency clauses that address tariff-related cost fluctuations. Importantly, the tariff adjustments have also underscored the value of supply chain transparency and traceability, encouraging greater investment in analytics and scenario planning to preserve programmatic resilience. While tariffs represent a macro-level shift, their most tangible impacts emerge through operational changes at manufacturing sites, distribution hubs, and procurement desks.

Deep segmentation-driven insights revealing how vaccine type, administration route, formulation, presentation, distribution, end-user, age group, and application determine product and program choices

Segmentation insights illuminate how product attributes and delivery contexts shape clinical utility, commercial strategy, and programmatic fit. Based on vaccine type, the field differentiates between injectable vaccine options and oral vaccine formulations, with each pathway carrying distinct clinical, logistical, and acceptance considerations; injectable vaccines may align with clinical settings seeking durable immune responses, whereas oral vaccines often prioritize ease of administration during mass campaigns and rapid outbreak response. Based on route of administration, distinctions between intramuscular and oral delivery influence provider training, patient acceptance, and site-of-care selection; intramuscular routes typically require trained personnel and sharps management, while oral administration reduces those operational burdens and can expand reach in community campaigns.

Based on dosage form, liquid and lyophilized presentations present trade-offs related to stability, reconstitution requirements, and cold-chain dependencies; liquid forms facilitate rapid deployment, while lyophilized formulations can extend shelf life under certain storage profiles. Based on presentation type, multi dose and single dose packaging choices affect wastage rates, storage space, and per-administration cost dynamics; multi dose vials may improve supply efficiency in high-throughput settings but necessitate stringent protocols to prevent contamination. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each offer unique access points that influence uptake patterns, patient counseling opportunities, and reimbursement interactions; hospital pharmacies commonly support institutional immunization programs, online pharmacies enable direct-to-consumer access in regulated contexts, and retail pharmacies provide convenient touchpoints for routine immunization. Based on end user, diverse delivery environments such as ambulatory centers, clinics, hospitals, and research facilities impose differing logistical and clinical requirements that manufacturers must account for in product design and support services. Based on age group, adult, geriatric, and pediatric segments drive formulation, dosing, and safety monitoring priorities because immune response and risk profiles vary across the lifespan. Based on application, prophylactic and therapeutic use cases determine evidence needs, with prophylactic vaccination focusing on prevention and population-level protection, while therapeutic applications demand data regarding use in outbreak containment or as adjuncts to clinical care. Collectively, these segmentation dimensions guide targeted product development, tailored messaging for providers and payers, and differentiated commercialization strategies that align with the operational realities of delivery environments.

Regional dynamics that shape regulatory approaches, procurement modalities, manufacturing linkages, and deployment strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics materially influence policy priorities, regulatory approaches, and supply chain architectures for cholera vaccination programs. In the Americas, public health systems tend to emphasize integration of vaccines into established immunization schedules and contingency planning for localized outbreaks, supported by public procurement frameworks that favor transparent contracting and centralized distribution. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory environments and health system capacities, where regional coordination mechanisms and donor-funded initiatives play a large role in harmonizing access and standardizing emergency response protocols.

Meanwhile, the Asia-Pacific region demonstrates a combination of manufacturing capacity growth and large, diverse population needs that create both opportunity and complexity. Across these geographies, regional manufacturers and global suppliers must adapt to varying cold-chain infrastructures, differing regulatory timelines, and distinct stakeholder expectations. As a result, successful strategies increasingly couple technical product attributes with tailored market access plans that reflect local procurement models, reimbursement mechanisms, and public health priorities. Transitional investments in regional distribution hubs and capacity-building programs further influence how quickly and effectively vaccination efforts scale in response to epidemiological signals.

Corporate strategic directions and partnership models that determine competitive advantage through manufacturing scale, platform innovation, and programmatic support commitments

Competitive positioning among leading companies reflects divergent strategies around innovation, supply agreements, and partnerships with public health institutions. Some organizations emphasize platform investments that enable rapid iteration of oral and injectable candidates, while others concentrate on optimizing manufacturing processes and expanding fill-finish capacity to meet the needs of large-scale campaigns. Strategic alliances between commercial manufacturers and global health agencies have become common, focused on jointly addressing affordability, supply predictability, and distribution to hard-to-reach populations.

Additionally, companies that invest in programmatic support services-such as training, cold-chain solutions, and post-market surveillance systems-tend to strengthen their value propositions with national immunization programs and large procurers. Intellectual property strategies and manufacturing licensing arrangements also influence market access; technology transfers to regional producers can accelerate local availability but require careful management of quality assurance and regulatory compliance. Overall, competitive differentiation increasingly rests on the ability to align product attributes with implementation realities, maintain resilient supply networks, and demonstrate commitment to public health outcomes through measurable program support.

Practical and prioritized strategic actions for manufacturers and public health partners to align product design, supply resilience, pricing, and programmatic support for maximal impact

Actionable recommendations for industry leaders emphasize aligning scientific development with practical delivery and stakeholder engagement. First, prioritize product design decisions that account for end-user contexts and distribution realities, ensuring that formulation and packaging choices reduce logistical friction and support rapid outbreak response. Second, invest in diversified supplier networks and regional manufacturing partnerships to mitigate trade and tariff exposure while enhancing responsiveness to local demand. Third, augment commercial offerings with programmatic support such as training, cold-chain innovation, and post-deployment surveillance to strengthen relationships with health authorities and procurers.

Moreover, develop flexible contracting and pricing frameworks that recognize the constraints of public-sector purchasers and international donors, and incorporate contingency clauses that address regulatory or trade disruptions. Finally, commit to transparent data-sharing arrangements and collaborative research partnerships that accelerate evidence generation around real-world effectiveness and safety, thereby building confidence among clinicians, policymakers, and communities. Taken together, these recommendations encourage a balanced approach that integrates scientific rigor, operational resilience, and stakeholder-centered engagement.

A robust mixed-methods research framework combining expert interviews, literature synthesis, and triangulated analysis to ensure evidence-based and actionable insights

The research methodology underpinning this report employed a mixed-methods approach that combined comprehensive literature synthesis, expert interviews, and qualitative analysis of policy and procurement documents. Primary research included structured consultations with vaccine developers, supply chain specialists, and immunization program managers to gather firsthand perspectives on operational challenges and opportunities. Secondary research integrated peer-reviewed studies, regulatory filings, and programmatic guidance to corroborate themes and ensure an evidence-based narrative.

Analytical frameworks emphasized triangulation: insights derived from stakeholder interviews were cross-checked against documented regulatory developments and published clinical outcomes to strengthen validity. Where appropriate, scenario analysis was used to explore operational implications of trade and policy shifts, and sensitivity testing helped highlight potential points of vulnerability in supply networks. Throughout, quality assurance processes ensured that data sources were critiqued for relevance and recency, and that conclusions reflected convergent evidence rather than isolated observations.

A forward-looking conclusion emphasizing the convergence of innovation, supply resilience, and stakeholder collaboration necessary to translate vaccine advances into public health gains

In conclusion, the cholera vaccine domain is at an inflection point where scientific advances, supply chain modernization, and evolving policy demands are converging to reshape how vaccines are developed, procured, and delivered. Innovations in formulation and presentation expand the toolkit available to public health practitioners, while changes in trade and procurement practices remind stakeholders of the need for operational agility. As a result, success will favor organizations that integrate technical excellence with pragmatic programmatic support and resilient commercial strategies.

Looking ahead, sustained collaboration between manufacturers, health authorities, funders, and regional production partners will be essential to translate scientific progress into meaningful reductions in disease burden. By adopting the strategic priorities outlined here-centered on product suitability, supply chain diversification, and stakeholder engagement-actors across the ecosystem can improve preparedness for outbreaks and enhance routine protection. These coordinated efforts will ultimately determine the degree to which vaccine innovations realize their full public health potential.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cholera Vaccines Market, by Vaccine Type

  • 8.1. Injectable Vaccine
  • 8.2. Oral Vaccine

9. Cholera Vaccines Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Oral

10. Cholera Vaccines Market, by Dosage Form

  • 10.1. Liquid
  • 10.2. Lyophilized

11. Cholera Vaccines Market, by Presentation Type

  • 11.1. Multi Dose
  • 11.2. Single Dose

12. Cholera Vaccines Market, by Age Group

  • 12.1. Adult
  • 12.2. Geriatric
  • 12.3. Pediatric

13. Cholera Vaccines Market, by Application

  • 13.1. Prophylactic
  • 13.2. Therapeutic

14. Cholera Vaccines Market, by End User

  • 14.1. Ambulatory Centers
  • 14.2. Clinics
  • 14.3. Hospitals
  • 14.4. Research Facilities

15. Cholera Vaccines Market, by Distribution Channel

  • 15.1. Hospital Pharmacy
  • 15.2. Online Pharmacy
  • 15.3. Retail Pharmacy

16. Cholera Vaccines Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Cholera Vaccines Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Cholera Vaccines Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Cholera Vaccines Market

20. China Cholera Vaccines Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. AstraZeneca PLC
  • 21.6. Bavarian Nordic A/S
  • 21.7. Bharat Biotech International Limited
  • 21.8. Emergent BioSolutions Inc.
  • 21.9. EuBiologics Co. Ltd.
  • 21.10. GlaxoSmithKline PLC
  • 21.11. Johnson & Johnson
  • 21.12. Merck & Co. Inc.
  • 21.13. Mitsubishi Tanabe Pharma Corporation
  • 21.14. Novartis AG
  • 21.15. PaxVax Inc.
  • 21.16. Pfizer Inc.
  • 21.17. Sanofi Pasteur SA
  • 21.18. Serum Institute of India Pvt. Ltd.
  • 21.19. Shantha Biotechnics Limited
  • 21.20. Takeda Pharmaceutical Company Limited
  • 21.21. Valneva SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHOLERA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHOLERA VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CHOLERA VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHOLERA VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHOLERA VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES CHOLERA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA CHOLERA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHOLERA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INJECTABLE VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INJECTABLE VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INJECTABLE VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CHOLERA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LYOPHILIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHOLERA VACCINES MARKET SIZE, BY LYOPHILIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHOLERA VACCINES MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHOLERA VACCINES MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CHOLERA VACCINES MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHOLERA VACCINES MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CHOLERA VACCINES MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHOLERA VACCINES MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHOLERA VACCINES MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHOLERA VACCINES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHOLERA VACCINES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHOLERA VACCINES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AMBULATORY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CHOLERA VACCINES MARKET SIZE, BY AMBULATORY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHOLERA VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHOLERA VACCINES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHOLERA VACCINES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RESEARCH FACILITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RESEARCH FACILITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RESEARCH FACILITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHOLERA VACCINES MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CHOLERA VACCINES MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHOLERA VACCINES MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CHOLERA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS CHOLERA VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL CHOLERA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. GCC CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. GCC CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 157. GCC CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GCC CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. GCC CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GCC CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. G7 CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. G7 CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 183. G7 CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 184. G7 CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. G7 CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. G7 CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. G7 CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. NATO CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. NATO CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 193. NATO CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. NATO CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 196. NATO CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. NATO CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL CHOLERA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES CHOLERA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA CHOLERA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA CHOLERA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA CHOLERA VACCINES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA CHOLERA VACCINES MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA CHOLERA VACCINES MARKET SIZE, BY PRESENTATION TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA CHOLERA VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA CHOLERA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA CHOLERA VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA CHOLERA VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)